Form SD - Specialized disclosure report
May 31 2024 - 4:21PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
SD
SPECIALIZED
DISCLOSURE REPORT
GSK
plc
(Exact
name of Registrant as specified in its charter)
England
and Wales |
|
001-15170 |
|
98-0607772 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification No.) |
GSK
plc
980
Great West Road
Brentford,
TW8 9GS
England
(Address
of principal executive offices)
Victoria
Whyte
Company
Secretary
+44
20 8047 5000
(Name
and telephone number of this person to contact in connection with this report)
Check
the appropriate box to indicate the rule pursuant to which this form is being filed:
☒ Rule
13p-l under the Securities Exchange Act (17 CFR240.13p-l) for the reporting period from January 1 to December 31, 2023.
☐ Rule
13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended ______.
Section
1 – Conflict Minerals Disclosure
Item
1.01 Conflict Minerals Disclosure and Report
Rule
13p-1 under the Securities Exchange Act of 1934, as amended, (the “Rule”) generally provides that a company must file
a specialized disclosure report if it manufactures or contracts to manufacture products for which one or more of the following minerals
are necessary to the functionality or production of the company’s products: cassiterite; columbite-tantalite (coltan); and
wolframite; their derivatives tantalum, tin, and tungsten; and gold (collectively, “3TGs”). These are considered “conflict
minerals” under the Rule regardless of their geographic origin and whether or not they fund armed conflict in the Democratic
Republic of the Congo or its neighboring countries (the “covered countries”).
GSK
is a global biopharma company that researches and develops a broad range of innovative products. GSK prevents and treats diseases
with vaccines, specialty and general medicines. GSK focuses on the science of the immune system and advanced technologies, investing
in four core therapeutic areas: infectious diseases, HIV, respiratory/immunology, and oncology. GSK
obtains (i) materials from suppliers for manufacturing purposes and (ii) finished products from contract manufacturing organizations
(“CMOs”) for sales and distribution by GSK.
Pursuant
to the Rule, we conducted in good faith a technical review of GSK’s products and surveyed our suppliers and CMOs. This review
and survey was updated via ongoing monitoring for calendar year 2023 to determine whether 3TGs were present in our products. For
those products that did contain 3TGs, we conducted in good faith a reasonable country of origin inquiry that GSK believes was reasonably
designed to determine whether any 3TG necessary to the functionality or production of these materials or products originated in the
covered countries or was not from recycled or scrap sources. For any materials or products containing 3TGs, we requested information
from the applicable suppliers and CMOs regarding the source of such 3TGs. None of the suppliers or CMOs indicated to us that any
3TGs contained in the materials or products they provided to GSK in 2023 came from the covered countries or were not from recycled
or scrap sources.
In
summary, as a result of our diligence on the suppliers and CMOs, we have no reason to believe that any of the 3TGs contained in our
2023 products that are within the scope of the Rule originated in the covered countries or were not from recycled or scrap sources.
The
information in this Form SD is also publicly available on our website at www.gsk.com/en-gb/company/codes-standards-and-reports/#conflict-minerals-report.
|
Item
1.02 Exhibit
Not
applicable.
Section
2 – Resource Extraction Issuer Disclosure
Item
2.01 Resource Extraction Issuer Disclosure and Report
Not
applicable.
Section
3 – Exhibits
Item
3.01 Exhibits
Not
applicable.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the duly authorized undersigned.
|
|
/s/ Julie Brown |
Dated:
May 31, 2024 |
|
Name:
Julie Brown |
|
|
Title:
Chief Financial Officer |
GSK (PK) (USOTC:GLAXF)
Historical Stock Chart
From May 2024 to Jun 2024
GSK (PK) (USOTC:GLAXF)
Historical Stock Chart
From Jun 2023 to Jun 2024